294 related articles for article (PubMed ID: 23244823)
1. What is wrong with orphan drug policies?
Côté A; Keating B
Value Health; 2012 Dec; 15(8):1185-91. PubMed ID: 23244823
[TBL] [Abstract][Full Text] [Related]
2. What is wrong with orphan drug policies? Suggestions for ways forward.
Kanavos P; Nicod E
Value Health; 2012 Dec; 15(8):1182-4. PubMed ID: 23244822
[TBL] [Abstract][Full Text] [Related]
3. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
4. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
5. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
Valverde AM; Reed SD; Schulman KA
Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
[TBL] [Abstract][Full Text] [Related]
6. Pricing and reimbursement of orphan drugs: the need for more transparency.
Simoens S
Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
[TBL] [Abstract][Full Text] [Related]
7. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
8. CMS move threatens to put orphan drugs out in cold.
Carroll J
Manag Care; 2003 Jul; 12(7):10-1. PubMed ID: 12891947
[No Abstract] [Full Text] [Related]
9. Getting to the Root of High Prescription Drug Prices.
Waxman H; Corr B; Martin K; Duong S
Issue Brief (Commonw Fund); 2017 Jul; 2017():1-10. PubMed ID: 28700190
[TBL] [Abstract][Full Text] [Related]
10. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
[TBL] [Abstract][Full Text] [Related]
11. [Orphan drugs: some legal, ethical and economics aspects].
Pabst JY
Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
[TBL] [Abstract][Full Text] [Related]
12. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
13. PhRMA sues on 340B orphans.
Lee J
Mod Healthc; 2013 Oct; 43(40):17. PubMed ID: 24340726
[No Abstract] [Full Text] [Related]
14. Saving orphan drug legislations: misconceptions and clarifications.
Hyry HI; Cox TM; Roos JC
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):111-7. PubMed ID: 26768506
[TBL] [Abstract][Full Text] [Related]
15. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
Arno PS; Bonuck K; Davis M
Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947
[TBL] [Abstract][Full Text] [Related]
16. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
Gammie T; Lu CY; Babar ZU
PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948
[TBL] [Abstract][Full Text] [Related]
17. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
18. The prevalence and cost of unapproved uses of top-selling orphan drugs.
Kesselheim AS; Myers JA; Solomon DH; Winkelmayer WC; Levin R; Avorn J
PLoS One; 2012; 7(2):e31894. PubMed ID: 22363762
[TBL] [Abstract][Full Text] [Related]
19. Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door.
Yang YT; Chen B; Bennett CL
J Clin Oncol; 2016 Dec; 34(36):4320-4322. PubMed ID: 27998222
[No Abstract] [Full Text] [Related]
20. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O; Zhou Y
Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
